ArticleAntimicrobial agents and chemotherapy2014
Discovery of novel antigiardiasis drug candidates.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Giardiasis in the Immunocompromised: A Case Series Highlighting Diagnostic Pitfalls and Treatment Challenges.Cureus · 2025Article
- An Improved Method to Enrich Large Extracellular Vesicles Derived fromLife (Basel, Switzerland) · 2023Article
- Identification of Fungus-Derived Natural Products as New Antigiardial Scaffolds.Microbiology spectrum · 2023Article
- Ultrastructural Alterations of the Human PathogenPathogens (Basel, Switzerland) · 2023Review
- Antigiardial Activity of Novel Guanidine Compounds.ChemMedChem · 2022Article
- An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives.Frontiers in cellular and infection microbiology · 2022Review
- Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives.Antimicrobial agents and chemotherapy · 2020Article
- Enhanced Antigiardial Effect of Omeprazole Analog Benzimidazole Compounds.Molecules (Basel, Switzerland) · 2020Article
- Treatment-refractory giardiasis: challenges and solutions.Infection and drug resistance · 2018Review
- Novel giardicidal compounds bearing proton pump inhibitor scaffold proceeding through triosephosphate isomerase inactivation.Scientific reports · 2017Article
- Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis.International journal for parasitology. Drugs and drug resistance · 2017Article
- A novel in vitro image-based assay identifies new drug leads for giardiasis.International journal for parasitology. Drugs and drug resistance · 2017Article
- The Critical Role of the Cytoskeleton in the Pathogenesis ofCurrent clinical microbiology reports · 2015Article
- Infections by Intestinal Coccidia and Giardia duodenalis.Clinics in laboratory medicine · 2015Review
- Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia.Frontiers in microbiology · 2015Review
- Drug Resistance in the Microaerophilic ParasiteCurrent tropical medicine reportsReview
- AIranian journal of parasitologyArticle
- Perspective on the Genetic Response to Antiparasitics: A Review Article.Iranian journal of parasitologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Giardiasis is a severe intestinal parasitic disease caused by Giardia lamblia, which inflicts many people in poor regions and is the most common parasitic infection in the United States. Current standard care drugs are associated with undesirable side effects, treatment failures, and an increasing incidence of drug resistance. As follow-up to a high-throughput screening of an approved drug library, which identified compounds lethal to G. lamblia trophozoites, we have determined the minimum lethal concentrations of 28 drugs and advanced 10 of them to in vivo studies in mice. The results were compared to treatment with the standard care drug, metronidazole, in order to identify drugs with equal or better anti-Giardia activities. Three drugs, fumagillin, carbadox, and tioxidazole, were identified. These compounds were also potent against metronidazole-resistant human G. lamblia isolates (assemblages A and B), as determined in in vitro assays. Of these three compounds, fumagillin is currently an orphan drug used within the European Union to treat microsporidiosis in immunocompromised individuals, whereas carbadox and tioxidazole are used in veterinary medicine. A dose-dependent study of fumagillin in a giardiasis mouse model revealed that the effective dose of fumagillin was ∼ 100-fold lower than the metronidazole dose. Therefore, fumagillin may be advanced to further studies as an alternative treatment for giardiasis when metronidazole fails.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.